Biogen/$BIIB

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Biogen

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.

Ticker

$BIIB
Sector
Health Care
Primary listing
NASDAQ

Industry

Biotechnology
Headquarters
Cambridge, United States

Employees

7,605
Website
www.biogen.com

Biogen Metrics

BasicAdvanced
$19B
12.24
$10.45
-
-

What the Analysts think about Biogen

Analyst ratings (Buy, Hold, Sell) for Biogen stock.

Bulls say / Bears say

Biogen's Alzheimer's drug, Leqembi, generated $40 million in sales in Q2 2024, surpassing Wall Street expectations and indicating strong market potential. (reuters.com)
The acquisition of Reata Pharmaceuticals added Skyclarys to Biogen's portfolio, which generated $78 million in Q1 2025, exceeding forecasts and enhancing the company's rare disease pipeline. (nasdaq.com)
Biogen's cost-cutting initiatives, including a $1 billion restructuring program, are expected to generate significant savings, allowing reinvestment into new products and R&D. (nasdaq.com)
Biogen anticipates a mid-single-digit percentage revenue decline in 2025, excluding currency impacts, due to strong competition for its multiple sclerosis drugs. (reuters.com)
The launch of Leqembi has been slow in the U.S. due to complex requirements, including diagnostic tests and regular brain scans, potentially hindering its market adoption. (reuters.com)
Biogen's multiple sclerosis drug sales, including Tecfidera, fell by 4.9% to $1.15 billion in Q2 2024, reflecting ongoing challenges in its core business. (reuters.com)
Data summarised monthly by Lightyear AI. Last updated on 7 Jul 2025.

Biogen Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Biogen Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

Biogen News

AllArticlesVideos
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

CNBC Television·3 hours ago
Biogen raises annual profit forecast on strong demand for rare disease drugs

Biogen raises annual profit forecast on strong demand for rare disease drugs

Reuters·1 day ago
Patients still benefit from Eisai and Biogen Alzheimer's drug after four years, study finds

Patients still benefit from Eisai and Biogen Alzheimer's drug after four years, study finds

Reuters·2 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $BIIB

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs